Taysha gene therapies announces participation in upcoming investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the truist fireside chat series as well as the 10th annual svb leerink global healthcare conference. conferences details: e
TSHA Ratings Summary
TSHA Quant Ranking